Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies.
Singh H, Srour SA, Milton DR, McCarty J, Dai C, Gaballa MR, Ammari M, Olivares S, Huls H, De Groot E, Marin D, Petropoulos D, Olson AL, Anderlini P, Im JS, Khouri I, Hosing CM, Rezvani K, Champlin RE, Shpall EJ, Cooper LJN, Kebriaei P. Singh H, et al. Among authors: im js. Front Immunol. 2022 Nov 10;13:1032397. doi: 10.3389/fimmu.2022.1032397. eCollection 2022. Front Immunol. 2022. PMID: 36439104 Free PMC article. Clinical Trial.
Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations.
Ciurea SO, Chilkulwar A, Saliba RM, Chen J, Rondon G, Patel KP, Khogeer H, Shah AR, Randolph BV, Perez JMR, Popat U, Hosing CM, Bashir Q, Mehta R, Al-Atrash G, Im J, Khouri IF, Kebriaei P, Champlin RE. Ciurea SO, et al. Blood. 2018 Jun 28;131(26):2989-2992. doi: 10.1182/blood-2018-02-832360. Epub 2018 May 16. Blood. 2018. PMID: 29769261 Free PMC article. No abstract available.
Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease.
Trujillo-Ocampo A, Cho HW, Herrmann AC, Ruiz-Vazquez W, Thornton AB, He H, Li D, Qazilbash MA, Ma Q, Porcelli SA, Shpall EJ, Molldrem J, Im JS. Trujillo-Ocampo A, et al. Among authors: im js. Cytotherapy. 2018 Aug;20(8):1089-1101. doi: 10.1016/j.jcyt.2018.05.007. Epub 2018 Jul 31. Cytotherapy. 2018. PMID: 30076070 Free PMC article.
Is a matched unrelated donor search needed for all allogeneic transplant candidates?
Ciurea SO, Bittencourt MCB, Milton DR, Cao K, Kongtim P, Rondon G, Chen J, Konopleva M, Perez JMR, El Shazly MF, Aljadayeh M, Alvarez M, Im J, Al-Atrash G, Mehta R, Popat U, Bashir Q, Oran B, Hosing CM, Khouri IF, Kebriaei P, Champlin RE. Ciurea SO, et al. Blood Adv. 2018 Sep 11;2(17):2254-2261. doi: 10.1182/bloodadvances.2018021899. Blood Adv. 2018. PMID: 30206098 Free PMC article.
Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome.
Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, Chilkulwar AR, Al-Atrash G, Alousi A, Andersson BS, Im JS, Hosing CM, Bashir Q, Khouri I, Kebriaei P, Oran B, Popat U, Champlin R, Ciurea SO. Kongtim P, et al. Among authors: im js. Bone Marrow Transplant. 2019 Jun;54(6):839-848. doi: 10.1038/s41409-018-0344-9. Epub 2018 Sep 26. Bone Marrow Transplant. 2019. PMID: 30258129 Free PMC article.
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.
Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Popat UR, et al. Among authors: im js. Lancet Haematol. 2018 Nov;5(11):e532-e542. doi: 10.1016/S2352-3026(18)30156-X. Lancet Haematol. 2018. PMID: 30389035 Free PMC article. Clinical Trial.
A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2.
Herrmann AC, Im JS, Pareek S, Ruiz-Vasquez W, Lu S, Sergeeva A, Mehrens J, He H, Alatrash G, Sukhumalchandra P, St John L, Clise-Dwyer K, Zha D, Molldrem JJ. Herrmann AC, et al. Among authors: im js. Front Immunol. 2019 Jan 18;9:3153. doi: 10.3389/fimmu.2018.03153. eCollection 2018. Front Immunol. 2019. PMID: 30713535 Free PMC article.
Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial.
Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Mehta RS, et al. Among authors: im js. Haematologica. 2019 Dec;104(12):e555-e557. doi: 10.3324/haematol.2018.214429. Epub 2019 Apr 4. Haematologica. 2019. PMID: 30948491 Free PMC article. Clinical Trial. No abstract available.
Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study.
Galloway-Peña JR, Peterson CB, Malik F, Sahasrabhojane PV, Shah DP, Brumlow CE, Carlin LG, Chemaly RF, Im JS, Rondon G, Felix E, Veillon L, Lorenzi PL, Alousi AM, Jenq RR, Kontoyiannis DP, Shpall EJ, Shelburne SA, Okhuysen PC. Galloway-Peña JR, et al. Among authors: im js. Open Forum Infect Dis. 2019 Apr 4;6(5):ofz173. doi: 10.1093/ofid/ofz173. eCollection 2019 May. Open Forum Infect Dis. 2019. PMID: 31065565 Free PMC article.
188 results